Clemens P Spielvogel1,2, Stefan Stoiber1,3, Laszlo Papp4, Denis Krajnc4, Marko Grahovac2, Elisabeth Gurnhofer3, Karolina Trachtova1,2,5, Vojtech Bystry5, Asha Leisser2, Bernhard Jank6, Julia Schnoell6, Lorenz Kadletz6, Gregor Heiduschka6, Thomas Beyer4, Marcus Hacker2, Lukas Kenner7,8, Alexander R Haug1,2. 1. Christian Doppler Laboratory for Applied Metabolomics, Vienna, Austria. 2. Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria. 3. Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria. 4. Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria. 5. Centre for Molecular Medicine, Central European Institute of Technology, Brno, Czech Republic. 6. Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Vienna, Vienna, Austria. 7. Christian Doppler Laboratory for Applied Metabolomics, Vienna, Austria. lukas.kenner@meduniwien.ac.at. 8. Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria. lukas.kenner@meduniwien.ac.at.
Abstract
PURPOSE: Head and neck squamous cell carcinomas (HNSCCs) are a molecularly, histologically, and clinically heterogeneous set of tumors originating from the mucosal epithelium of the oral cavity, pharynx, and larynx. This heterogeneous nature of HNSCC is one of the main contributing factors to the lack of prognostic markers for personalized treatment. The aim of this study was to develop and identify multi-omics markers capable of improved risk stratification in this highly heterogeneous patient population. METHODS: In this retrospective study, we approached this issue by establishing radiogenomics markers to identify high-risk individuals in a cohort of 127 HNSCC patients. Hybrid in vivo imaging and whole-exome sequencing were employed to identify quantitative imaging markers as well as genetic markers on pathway-level prognostic in HNSCC. We investigated the deductibility of the prognostic genetic markers using anatomical and metabolic imaging using positron emission tomography combined with computed tomography. Moreover, we used statistical and machine learning modeling to investigate whether a multi-omics approach can be used to derive prognostic markers for HNSCC. RESULTS: Radiogenomic analysis revealed a significant influence of genetic pathway alterations on imaging markers. A highly prognostic radiogenomic marker based on cellular senescence was identified. Furthermore, the radiogenomic biomarkers designed in this study vastly outperformed the prognostic value of markers derived from genetics and imaging alone. CONCLUSION: Using the identified markers, a clinically meaningful stratification of patients is possible, guiding the identification of high-risk patients and potentially aiding in the development of effective targeted therapies.
PURPOSE: Head and neck squamous cell carcinomas (HNSCCs) are a molecularly, histologically, and clinically heterogeneous set of tumors originating from the mucosal epithelium of the oral cavity, pharynx, and larynx. This heterogeneous nature of HNSCC is one of the main contributing factors to the lack of prognostic markers for personalized treatment. The aim of this study was to develop and identify multi-omics markers capable of improved risk stratification in this highly heterogeneous patient population. METHODS: In this retrospective study, we approached this issue by establishing radiogenomics markers to identify high-risk individuals in a cohort of 127 HNSCC patients. Hybrid in vivo imaging and whole-exome sequencing were employed to identify quantitative imaging markers as well as genetic markers on pathway-level prognostic in HNSCC. We investigated the deductibility of the prognostic genetic markers using anatomical and metabolic imaging using positron emission tomography combined with computed tomography. Moreover, we used statistical and machine learning modeling to investigate whether a multi-omics approach can be used to derive prognostic markers for HNSCC. RESULTS: Radiogenomic analysis revealed a significant influence of genetic pathway alterations on imaging markers. A highly prognostic radiogenomic marker based on cellular senescence was identified. Furthermore, the radiogenomic biomarkers designed in this study vastly outperformed the prognostic value of markers derived from genetics and imaging alone. CONCLUSION: Using the identified markers, a clinically meaningful stratification of patients is possible, guiding the identification of high-risk patients and potentially aiding in the development of effective targeted therapies.
Authors: Philippe Lambin; Ralph T H Leijenaar; Timo M Deist; Jurgen Peerlings; Evelyn E C de Jong; Janita van Timmeren; Sebastian Sanduleanu; Ruben T H M Larue; Aniek J G Even; Arthur Jochems; Yvonka van Wijk; Henry Woodruff; Johan van Soest; Tim Lustberg; Erik Roelofs; Wouter van Elmpt; Andre Dekker; Felix M Mottaghy; Joachim E Wildberger; Sean Walsh Journal: Nat Rev Clin Oncol Date: 2017-10-04 Impact factor: 66.675
Authors: Philipp Rentzsch; Daniela Witten; Gregory M Cooper; Jay Shendure; Martin Kircher Journal: Nucleic Acids Res Date: 2019-01-08 Impact factor: 16.971